NY0123

Overview

NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT , phosphorylated ERK1/2 and phosphorylated VEGFR2 . NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer . NY0123 is applicable to relevant research on triple-negative breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Ras | Products > Signaling Pathways > Akt | Products > Signaling Pathways > ERK

Product Information

• Catalog No.: HY-123795
• CAS No.: 1801911-70-5
• Molecular Formula: C16H13Cl3N4O2
• Molecular Weight: 399.66
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source